Current board rolesNuChem Therapeutics
Previous board rolesIBEX Technologies
Canadian Genetic Disease Network
EducationPhD (Organic Chemistry) University of Tasmania, Australia
Post-doctoral studies in Organic Chemistry, Institut de Chimie des Substances Naturelles, France
Industry affiliationsOttawa Life Sciences Council
Dr. John W. Gillard sits on the advisory board of Lumira Capital Partners and is an adjunct Professor at McGill University, Faculty of Medicine and President of BioGill Consultants Inc.
He is currently Vice President, Kalgene Pharmaceuticals Inc., a Lumira investee company.
Dr. Gillard has a strong background in research leadership and pharmaceutical product development. He has made contributions to numerous therapeutic fields, leading to over 70 scientific publications, 30 patents and the development of three block-buster drugs, including the breakthrough HIV/AIDS drug 3TC™.
Dr. Gillard was founder and Chief Scientific Officer and Executive Vice President of Aegera Therapeutics Inc. from 2000-2012; Chief Executive Officer of Apoptogen Inc. from 1997 to 2000, a genomics-based start-up from the University of Ottawa; Vice President of Research of BioChem Pharma Inc. from 1991 of 1996; and Director of Medicinal Chemistry of Merck & Co. from 1980 to 1991. Dr. Gillard has maintained close academic contacts throughout his industrial career as Director of the Board of the Canadian Genetic Diseases Network from 1992 to 2000 and the Ottawa Life Sciences Council. Dr. Gillard received his Ph.D. in organic and natural products chemistry, University of Tasmania and undertook Post-doctoral fellowships at Boston College; Dana Farber Cancer Institute, Harvard University and le Centre National de la Recherche Scientifique, Paris, France.